No Pain, Lots To Gain: Vertex Looks For Non-Opioid Drug Breakthrough

Phase III Readout Expected By Early 2024

Vertex is closing in on annual revenues of $10bn from its cystic fibrosis drugs, but non-opioid pain therapy candidate VX-548 could open up a whole new blockbuster revenue stream if Phase III studies go to plan.

Vertex Mobile

Vertex is continuing to ride high thanks to its near-monopoly in cystic fibrosis disease-modifying treatment, led by blockbuster Trikafta (elexacaftor/tezacaftor/ivacaftor).

The oral therapy earned $2bn and contributed to overall revenue growth of 13% in Q1, reflecting the expansion of its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip